SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced that interim results from the first-in-human ALKA-372-001 Phase I clinical trial of RXDX-101, the company’s proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, was selected for presentation in a poster discussion session at the 2014 Congress of the European Society for Medical Oncology (ESMO), which is being held from September 26-30, 2014 in Madrid, Spain.
Help employers find you! Check out all the jobs and post your resume.
